Compare GAIA & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | ONCY |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.7M | 106.1M |
| IPO Year | 1999 | 1999 |
| Metric | GAIA | ONCY |
|---|---|---|
| Price | $3.35 | $0.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $9.00 | $6.00 |
| AVG Volume (30 Days) | 70.9K | ★ 660.5K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $98,622,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $11.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.80 | N/A |
| 52 Week Low | $2.93 | $0.33 |
| 52 Week High | $6.39 | $1.51 |
| Indicator | GAIA | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 44.01 |
| Support Level | $3.65 | $0.88 |
| Resistance Level | $3.89 | $1.00 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 19.35 | 51.31 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.